Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects between 18 and 80 years of age;~* Scheduled to undergo primary unilateral first metatarsal bunionectomy;~* Anesthesiological and surgical procedures performed according to protocol;~* Moderate or severe baseline pain following bunionectomy on a VRS within 9 hours of termination of the continuous popliteal sciatic block or systemic analgesia;~* Pain following bunionectomy of at least 4 on an 11-point NRS within 9 hours of termination of the continuous popliteal sciatic block or systemic analgesia; American Society of Anesthesiologists (ASA) classification I-III.~Exclusion Criteria:~* History of seizure disorder;~* History of alcohol, medication or drug dependency, unstable psychological personality requiring intermittent or permanent treatment; severely impaired renal function, moderately or severely impaired hepatic function;~* Contraindications to, or history of allergy or hypersensitivity to CG5503, oxycodone, morphine, fentanyl hydrocodone, acetaminophen, heparin, or any compound planned to be used during the anesthesia, or their excipients;~* Pre-operative use within 12h prior to surgery or peri-operative use of non- steroidal anti-inflammatory drugs (NSAIDs);~* Treated regularly with opioid analgesic or NSAIDs within 30 days prior to screening;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CG5503 IR 75mg 4 to 6 hourly for 72 hours
- 2 (Type: ACTIVE_COMPARATOR): Morphine IR 30 mg 4 to 6 hourly for 72 hours
- 3 (Type: PLACEBO_COMPARATOR): Matching placebo 4 to 6 hourly for 72 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).